跳至主要内容
临床试验/CTIS2024-513328-40-00
CTIS2024-513328-40-00招募中1 期

SHORTCUT - Efficacy of 7 days versus 14 days of antibiotic therapy for acute pyelonephritis in kidney transplant recipients, a multicenter randomized non-inferiority trial - APHP200020

Assistance Publique Hopitaux De Paris0 个研究点目标入组 470 人开始时间: 2024年5月31日最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
入组人数
470

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 65+(—)
性别
All

入选标准

  • Age >18 years Kidney Transplant Recipients, APN defined by: fever (T°=38°C) (with or without clinical signs and/or symptoms of UTI) and pyuria (=104 white blood cells/mL or =10/mm3) and positive urine culture (uropathogen =103 CFU/mL susceptible to the empirically administrated antibiotic), No confirmed or suspected febrile non urinary bacterial infection, No urologic/renal complication at baseline imaging (abscess, obstruction...), Favourable early response to antibiotic treatment:( 48 to 60 hours after the first dose of antibiotic effective against the causative uropathogen) defined by: T°<38°C and improvement (or resolution) of signs and/or symptoms of urinary tract infection if present at diagnosis., Written informed consent

排除标准

  • Patients with any of the following conditions, First month post transplantation, -Current indwelling catheter (including bladder catheter, ureteral stents, percutaneous nephrostomy tubes), Neurogenic bladder, Enterocystoplasty, Immunodeficiency or immunosuppressive therapy not related to kidney transplantation, including hematologic malignancy, cancer, asplenia, neutropenia<500 neutrophils/mm3,, Pregnancy, breastfeeding, Hypersensitivity or previous severe adverse drug reaction to the antibiotic therapy, Unable or unwilling, in the judgment of the investigator, to comply with the protocol, Life expectancy<1 month, Patient under legal guardianship or without healthcare coverage, Severe or complicated condition, Homeless patient, Women with childbearing potential not using adequate contraception, Any rapidly progressing disease or immediately life-threatening illness, including, but not limited to, septic shock, current or impeding respiratory failure, acute heart or liver failure, Admission or stay in intensive care unit at baseline, Obstruction of the urinary tract, Renal, perinephric or prostatic abscess, prior inclusion in this study, current participation to another interventional study, Dual antibiotic therapy ((prophylactic antibiotic such as cotrimoxazole allowed) )(only 1 dose of aminoside is allowed before randomization)

研究者

相似试验